Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)

SHE:300204 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	158	53.91	85.18	264.99	85.01	140.57
Short-Term Investments	-	-	-	-	-	120.73
Trading Asset Securities	-	-	-	-	381.46	461.24
Cash & Short-Term Investments	158	53.91	85.18	264.99	466.47	722.54
Cash Growth	269.75%	-36.71%	-67.86%	-43.19%	-35.44%	-8.52%
Accounts Receivable	45.67	39.07	61.22	188.18	157.9	128.22
Other Receivables	0.94	0.64	1.14	1.38	1.18	1.29
Receivables	46.61	39.72	62.35	189.56	159.07	129.51
Inventory	30.1	22.18	20.93	18.83	25.01	38.09
Prepaid Expenses	-	0.01	0.01	-	-	-
Other Current Assets	70.7	61.8	70.41	55.69	37.9	13.17
Total Current Assets	305.41	177.62	238.89	529.06	688.44	903.32
Property, Plant & Equipment	216.68	235	261.36	290.58	312.43	295.17
Long-Term Investments	477.13	514.07	549.54	522.25	545.43	444.03
Goodwill	19.75	19.75	19.75	19.75	22.17	22.17
Other Intangible Assets	36.61	34.67	35.13	80.48	82.22	82.97
Long-Term Deferred Tax Assets	50.08	50.08	164	198.13	155.84	79.87
Long-Term Deferred Charges	143.9	117.84	62.57	26.97	5.29	20.51
Other Long-Term Assets	14.36	0.58	0.98	2.09	15.15	8.17
Total Assets	1,264	1,150	1,332	1,669	1,827	1,856
Accounts Payable	14.96	33.49	72.91	35.87	31.71	19.63
Accrued Expenses	8.95	67.71	83.85	158.73	150.01	127.99
Short-Term Debt	41.67	42.42	40.95	23.09	-	48
Current Portion of Leases	-	0.06	-	2.69	2.25	-
Current Income Taxes Payable	2.43	-	-	0.02	-	-
Current Unearned Revenue	3.3	3.89	2.86	3.27	1.34	1.14
Other Current Liabilities	52.6	6.88	7.6	8.1	11.33	11.43
Total Current Liabilities	123.98	154.45	208.17	231.77	196.64	208.2
Long-Term Leases	-	0.06	-	3.18	5.37	-
Long-Term Unearned Revenue	27.49	29.91	29.24	33.47	21.32	23.35
Long-Term Deferred Tax Liabilities	48.51	48.43	74.14	47.03	52.91	33.83
Other Long-Term Liabilities	204.24	-	-	-	-	3.32
Total Liabilities	404.22	232.85	311.55	315.45	276.25	268.7
Common Stock	477.77	477.77	477.77	475.36	476.03	476.03
Additional Paid-In Capital	558.6	570.95	534.46	519.36	536.44	531.08
Retained Earnings	-280.05	-249.37	-83.63	314.62	510.98	648
Treasury Stock	-	-	-	-	-43.68	-82.72
Comprehensive Income & Other	114.28	129.88	92.06	44.53	70.97	15.11
Total Common Equity	870.61	929.23	1,021	1,354	1,551	1,588
Minority Interest	-10.91	-12.47	-	-	-	-
Shareholders' Equity	859.7	916.76	1,021	1,354	1,551	1,588
Total Liabilities & Equity	1,264	1,150	1,332	1,669	1,827	1,856
Total Debt	41.73	42.54	40.95	28.96	7.63	48
Net Cash (Debt)	116.26	11.37	44.23	236.03	458.84	674.54
Net Cash Growth	172.83%	-74.28%	-81.26%	-48.56%	-31.98%	-14.60%
Net Cash Per Share	0.23	0.02	0.09	0.49	0.97	1.42
Filing Date Shares Outstanding	549.05	477.77	477.77	475.36	472.66	469.65
Total Common Shares Outstanding	549.05	477.77	477.77	475.36	472.66	469.65
Working Capital	181.43	23.18	30.72	297.28	491.8	695.12
Book Value Per Share	1.59	1.94	2.14	2.85	3.28	3.38
Tangible Book Value	814.24	874.81	965.78	1,254	1,446	1,482
Tangible Book Value Per Share	1.48	1.83	2.02	2.64	3.06	3.16
Buildings	-	215.93	214.75	184.57	183.64	183.07
Machinery	-	317.62	318.38	254.98	246.28	237.66
Construction In Progress	-	-	-	87.82	85.48	52.92

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.